Effect of sibutramine on blood pressure in patients with obesity and well-controlled hypertension or normotension.
OBJECTIVE
To assess the short-term effects of sibu-tramine on blood pressure (BP) and heart rate (HR) in normotensive and controlled hypertensive obese patients by using ambulatory blood pressure monitoring (ABPM).


METHODS
Before and 5 to 7 days after the initiation of sibutramine treatment (10 mg or 15 mg daily), when steady-state concentrations of sibutramine had been reached, ABPM was performed in 81 obese patients. Of this overall study group, 47 patients (26 with normoten-sion and 21 with controlled hypertension) received sibu-tramine in a dosage of 10 mg/day, and 34 patients (18 with normotension and 16 with controlled hypertension) received sibutramine in a dosage of 15 mg/day.


RESULTS
Office-measured systolic and diastolic BPs in normotensive and controlled hypertensive groups of patients with obesity were not significantly different before and after treatment with both doses of sibutramine. ABPM results for normotensive obese groups showed that mean systolic and diastolic BPs were not significantly different after treatment with either 10-mg or 15-mg daily doses of sibutramine, in comparison with baseline. Similarly, in the controlled hypertensive obese groups, the ABPM results were not significantly different before and after sibutramine treatment. Moreover, the mean HR did not change significantly after versus before sibutramine treatment in both dosage groups.


CONCLUSIONS
Sibutramine did not induce or exacerbate hypertension and had no effect on HR in normotensive and controlled hypertensive obese patients when used in either of two suggested daily doses (10 mg or 15 mg).
Gürsoy
Alptekin
A
Department of Endocrinology and Metabolic Diseases, Ankara University, School of Medicine, Ankara, Turkey.
Erdoğan
Murat Faik
MF
Cin
Mine Ozduman
MO
Cesur
Mustafa
M
Başkal
Nilgün
N
D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001067:Appetite Depressants / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology; D018660:Blood Pressure Monitoring, Ambulatory; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003503:Cyclobutanes / Q000494:pharmacology* / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy / Q000503:physiopathology*; D013997:Time Factors
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001067:Appetite Depressants; D002121:Calcium Channel Blockers; D003503:Cyclobutanes; D004232:Diuretics; C058254:sibutramine